Gatifloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
pramlintide
Amylin analogue · Antidiabetic agent (other glucose-lowering agent)
Amylin analogueAntidiabetic agent (other glucose-lowering agent)
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
C
FDA category + note
Top interactionssee all 2 →
- GatifloxacinSevereDatabaseDDInter
Mechanism
Pramlintide is a synthetic form of amylin, a peptide co-secreted with insulin from pancreatic β cells. It acts through amylin receptors in the hindbrain to reduce glucagon secretion, delay gastric emptying, and foster a feeling of satiety.
Indications
Adjunct treatment in type 1 diabetesAdjunct treatment in type 2 diabetes (in patients who take insulin with meals)adjuvant to meal-time insulin injection to suppress glycaemic peak in type 1 diabetes mellitusadjuvant to meal-time insulin injection to suppress glycaemic peak in type 2 diabetes mellitus
Pharmacokinetics
Duration
2–3 hours
Half-life
50 min
Bioavailability
30%–40%
Protein binding
Not extensively bound by plasma proteins
Metabolism
Primarily renal
Excretion
—
Side effects
Common
NauseaHypoglycemia (when added to insulin)reduction in body weight
Pregnancy & lactation
Pregnancy
C
Drug interactions
Insulin
Moderate
Textbook
Increased incidence and severity of hypoglycemia.
Prandial insulin doses should be reduced 30% to 50% at the time of pramlintide initiation and then retitrated.
Source: G&G 14e · p1041
10 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Glucose monitoring in diabetes
RSSDI · Endocrinology · 2024
Diabetes management during Ramadan
ADA · Endocrinology · 2025
Gestational diabetes mellitus
FOGSI · Obstetrics & Gynaecology · 2023
Fluid and electrolyte management in diabetes
RSSDI · Endocrinology · 2025
Type 2 diabetes in adults
ADA · Endocrinology · 2022
Ask House about pramlintide
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team